supergrowth
2021-11-29
Buy.
Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞股价因计划提高新冠药丸产量以对抗奥密克戎变种而上涨</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
8
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":600443485,"tweetId":"600443485","gmtCreate":1638193062251,"gmtModify":1638193062438,"author":{"id":3581854803062408,"idStr":"3581854803062408","authorId":3581854803062408,"authorIdStr":"3581854803062408","name":"supergrowth","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Buy.</p></body></html>","htmlText":"<html><head></head><body><p>Buy.</p></body></html>","text":"Buy.","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/600443485","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","kind":"news","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=zh_CN&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞股价因计划提高新冠药丸产量以对抗奥密克戎变种而上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p><p><blockquote>辉瑞公司首席执行官 Albert Bourla 证实，该制药商计划首次提高其 Paxlovid 抗病毒治疗药物的产量，以对抗新奥密克戎变种的传播。</blockquote></p><p> Pfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p><p><blockquote>辉瑞公司股价周一延续涨幅，此前该制药商表示正准备提高新冠病毒抗病毒治疗药物的产量，以应对新发现的奥密克戎变种的潜在影响。</blockquote></p><p> Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p><p><blockquote>辉瑞公司首席执行官阿尔伯特·布尔拉 (Albert Bourla) 周一告诉 CNBC，该制药商已承诺生产 8000 万剂其正在开发的抗病毒药物 Paxlovid，高于之前预测的 5000 万剂。</blockquote></p><p> The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p><p><blockquote>抗病毒治疗可能继续成为对这种变异的有效防御，这种变异首先在南非被发现，尽管科学家仍然担心它可能对疫苗结构和天然免疫都有抵抗力。</blockquote></p><p> Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.</p><p><blockquote>布尔拉还表示，辉瑞公司已经创建了一种新模板，如果需要，可以加快新疫苗的开发，以对抗奥密克戎病毒，并补充说，该制药商明年有能力生产多达40亿剂疫苗。</blockquote></p><p> Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p><p><blockquote>科学家和卫生官员尚未确定奥密克戎是否具有疫苗耐药性，世界卫生组织警告说，可能需要“几周”才能评估其全部潜力。</blockquote></p><p> Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p><p><blockquote>辉瑞股价在周一盘前交易中上涨 1.85%，开盘价为每股 55.0 美元。该股在周五午盘交易中创下54.94美元的历史新高。</blockquote></p><p> Earlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.</p><p><blockquote>本月早些时候，辉瑞公司表示将向美国卫生与公众服务部出售约 1000 万剂 Paxlovid 治疗药物，该药物目前正在接受美国食品和药物管理局的紧急使用批准 (EUA) 审查。</blockquote></p><p> At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p><p><blockquote>每片 530 美元的价格，比上个月与默克公司 MRK 商定的 700 美元价格便宜约 25%，该公司购买了 170 万剂其“molnupiravir”治疗“轻度至中度 Covid”的成年人。有进展为严重形式的疾病，或住院。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞股价因计划提高新冠药丸产量以对抗奥密克戎变种而上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant<blockquote>辉瑞股价因计划提高新冠药丸产量以对抗奥密克戎变种而上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-11-29 21:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p><p><blockquote>辉瑞公司首席执行官 Albert Bourla 证实，该制药商计划首次提高其 Paxlovid 抗病毒治疗药物的产量，以对抗新奥密克戎变种的传播。</blockquote></p><p> Pfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p><p><blockquote>辉瑞公司股价周一延续涨幅，此前该制药商表示正准备提高新冠病毒抗病毒治疗药物的产量，以应对新发现的奥密克戎变种的潜在影响。</blockquote></p><p> Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p><p><blockquote>辉瑞公司首席执行官阿尔伯特·布尔拉 (Albert Bourla) 周一告诉 CNBC，该制药商已承诺生产 8000 万剂其正在开发的抗病毒药物 Paxlovid，高于之前预测的 5000 万剂。</blockquote></p><p> The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p><p><blockquote>抗病毒治疗可能继续成为对这种变异的有效防御，这种变异首先在南非被发现，尽管科学家仍然担心它可能对疫苗结构和天然免疫都有抵抗力。</blockquote></p><p> Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.</p><p><blockquote>布尔拉还表示，辉瑞公司已经创建了一种新模板，如果需要，可以加快新疫苗的开发，以对抗奥密克戎病毒，并补充说，该制药商明年有能力生产多达40亿剂疫苗。</blockquote></p><p> Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p><p><blockquote>科学家和卫生官员尚未确定奥密克戎是否具有疫苗耐药性，世界卫生组织警告说，可能需要“几周”才能评估其全部潜力。</blockquote></p><p> Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p><p><blockquote>辉瑞股价在周一盘前交易中上涨 1.85%，开盘价为每股 55.0 美元。该股在周五午盘交易中创下54.94美元的历史新高。</blockquote></p><p> Earlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.</p><p><blockquote>本月早些时候，辉瑞公司表示将向美国卫生与公众服务部出售约 1000 万剂 Paxlovid 治疗药物，该药物目前正在接受美国食品和药物管理局的紧急使用批准 (EUA) 审查。</blockquote></p><p> At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p><p><blockquote>每片 530 美元的价格，比上个月与默克公司 MRK 商定的 700 美元价格便宜约 25%，该公司购买了 170 万剂其“molnupiravir”治疗“轻度至中度 Covid”的成年人。有进展为严重形式的疾病，或住院。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":620,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/600443485"}
精彩评论